MetaCap

NewAmsterdam Pharma N.V. (NAMS) vs Prestige Consumer Healthcare (PBH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Prestige Consumer Healthcare (PBH) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, losing 16.5% versus a loss of 51.9%. Over five years, NAMS leads with a +88.0% price change compared with -12.0% for PBH. Prestige Consumer Healthcare is the larger company by market cap ($2.35 billion vs $2.21 billion), about 1.1 times the size.

Prestige Consumer Healthcare converts more of its revenue into profit, with a net margin of 17.5% versus -905.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NAMS-51.89%PBH-16.48%
+22%-17%-55%
Nov 21, 20251 yearNov 20, 2026
NAMS+87.47%PBH-14.81%
+338%+144%-49%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NAMS versus PBH key metrics
MetricNAMSPBH
Share price$18.41$49.63
Market cap$2.21B$2.35B
1-day change-5.64%+0.06%
YTD return-47.52%-19.55%
1-year return-51.89%-16.48%
5-year return+88.05%-12.02%
P/E ratio (TTM)—15.32
Forward P/E—9.76
EPS (TTM)$-1.69$3.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$22.50M$1.09B
Revenue growth (YoY)-50.61%-4.31%
Net income (latest FY)$-203.82M$190.30M
Gross margin—54.71%
Operating margin-1002.90%28.42%
Net margin-905.74%17.48%
52-week high$42.21$71.07
52-week low$17.90$41.77
Distance from 52-week high-56.38%-30.17%
Analyst consensusstrong_buybuy
Avg. price target upside+174.85%+33.39%
Average volume1.66M583.25K
Shares outstanding119.93M47.40M
Employees100890
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PBH has outperformed NAMS by 35.4 percentage points over the past year.
  • Prestige Consumer Healthcare is more profitable, keeping 17.5 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
  • Prestige Consumer Healthcare grew revenue faster in its latest fiscal year (-4.31% vs -50.61%).

About NewAmsterdam Pharma N.V.

NAMS stock →

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Prestige Consumer Healthcare

PBH stock →

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees

NAMS vs PBH FAQ

Which is bigger, NewAmsterdam Pharma N.V. or Prestige Consumer Healthcare?

Prestige Consumer Healthcare (PBH) is larger, with a market capitalization of $2.35B compared with $2.21B for NewAmsterdam Pharma N.V. (NAMS).

Which stock has performed better over the past year, NAMS or PBH?

PBH returned -16.48% over the past 12 months, compared with -51.89% for NAMS (price return, excluding dividends). Past performance does not predict future results.

Are NewAmsterdam Pharma N.V. and Prestige Consumer Healthcare in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons